文献速递妇科

艾立布林单药治疗晚期或复发性宫颈癌的两阶段II期临床试验

Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
PubMed 文献 · Gynecol Oncol · 2023-04-18

这项两阶段II期试验纳入32例晚期或复发性宫颈癌患者,接受艾立布林1.4 mg/m2静脉注射第1天和第8天、每21天一个周期。客观缓解率为19%(95%CI 8,37),紫杉醇未治者缓解率29%(95%CI 12,54)。常见3/4级不良事件为贫血38%、中性粒细胞减少22%、白细胞减少19%。

要点

  • 艾立布林在晚期或复发性宫颈癌中显示适度活性,客观缓解率19%(95%CI 8,37)。
  • 既往紫杉醇治疗者缓解较差(p=.002)且无进展生存期和总生存期更短。
  • βII、βIII微管蛋白亚型和BAX过表达与缓解及生存相关。

核心结论

  • 艾立布林在复发性或晚期宫颈癌中显示适度活性且毒性特征良好。
  • 既往紫杉醇暴露与艾立布林缓解降低相关。
  • βII、βIII微管蛋白亚型和BAX是缓解和生存的预测因子。
  • 艾立布林可能为紫杉醇未治的复发性或晚期宫颈癌女性的一种选择。

研究设计与样本

  • 两阶段II期临床试验,纳入32例既往化疗方案不超过1个、有可测量病灶且ECOG体能状态≤2的晚期或复发性宫颈癌女性。
  • 艾立布林1.4 mg/m2静脉注射第1天和第8天,每21天一个周期,每2个周期评估肿瘤。
  • 主要终点为6个月无进展生存率,次要终点为最佳总体缓解(RECISTv1.1)、毒性(CTCAEv4.03)和总生存期。
  • 探索性终点为生物标志物与临床活性的关联,对存档肿瘤样本进行免疫组化,过表达定义为强度和分布评分均≥2。
  • 患者入组时间为2012年11月至2017年5月。

主要发现

  • 32例中29例既往接受过化疗,最常见方案为顺铂/紫杉醇/贝伐珠单抗(n=12)或顺铂/吉西他滨(n=12),14例既往接受过紫杉醇。
  • 1例(3%)完全缓解,5例(16%)部分缓解,13例(41%)疾病稳定,客观缓解率为19%(95%CI 8,37)。
  • 紫杉醇未治者获益最大,客观缓解率为29%(95%CI 12,54);既往接受紫杉醇者缓解不如未接受者(p=.002),且无进展生存期和总生存期更短。
  • 发生率>10%的3/4级不良事件为贫血(n=12,38%)、中性粒细胞减少(n=7,22%)和白细胞减少(n=6,19%)。
  • βII和BAX未过表达者显著更可能对艾立布林缓解;βII和BAX过表达者无进展生存期显著更短,βIII和BAX过表达者总生存期显著更短,多因素分析后关联仍存在。

关键数值与推荐

  • 客观缓解率19%(95%CI 8,37),其中完全缓解1例(3%)、部分缓解5例(16%)、疾病稳定13例(41%)。
  • 紫杉醇未治者客观缓解率29%(95%CI 12,54)。
  • 既往接受紫杉醇者与未接受者缓解差异p=.002。
  • 3/4级贫血38%(n=12)、中性粒细胞减少22%(n=7)、白细胞减少19%(n=6)。

临床怎么用

  • 作者认为艾立布林可能为紫杉醇未治的复发性或晚期宫颈癌女性的一种选择。
  • 作者指出既往紫杉醇暴露与艾立布林缓解降低相关。
  • 作者指出βII、βIII微管蛋白亚型和BAX是缓解和生存的预测因子。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eribulin a microtubule targeting agent and analog of Halichondrin B, a natural product isolated from marine sponge H. okadai, has proven clinical efficacy in metastatic pretreated breast cancer and liposarcoma. We conducted a 2-stage Phase II study of eribulin in patients with advanced/recurrent cervical cancer to examine its clinical activity and evaluate biomarkers for predictors of response. METHODS: Women with advanced/recurrent cervical cancer after ≤1 prior chemotherapy regimen, measurable disease and ECOG performance status ≤2 were treated with eribulin (1.4 mg/m2 IV day 1 and 8, every 21 days) with tumor assessments every 2 cycles. Primary endpoint was 6-month progression-free survival (PFS6); secondary were best overall response (RECISTv1.1), toxicity (CTCAEv4.03) and overall survival (OS). Exploratory endpoints were associations of biomarkers with clinical activity. Immunohistochemistry was performed on archival tumor samples. Overexpression was defined when both intensity and distribution scores were ≥ 2. RESULTS: 32 patients enrolled from 11/2012-5/2017. 29/32 patients had prior chemotherapy with cisplatin/paclitaxel/bevacizumab (n = 12) or cisplatin/gemcitabine (n = 12) as the most common regimens. 14 patients received prior paclitaxel. 1 (3%) had a complete response, 5 (16%) had a partial response and 13 (41%) had stable disease for ORR of 19% (95% CI 8, 37). Those who are paclitaxel naïve experienced the greatest benefit with a 29% ORR (95% CI 12, 54). Patients who received prior paclitaxel responded less favorably than those who did not (p = .002) and had a shorter PFS and OS. Grade 3/4 adverse events occurring in >10% of patients were anemia (n = 12, 38%), neutropenia (n = 7, 22%) and leukopenia (n = 6, 19%). Analysis of correlative predictors of response revealed that patients who did not overexpress βII and BAX were significantly more likely to respond to e`ribulin. PFS was significantly shorter in patients with βII and BAX overexpression, OS was significantly shorter in those with βIII and BAX overexpression. These associations remained after multivariate analysis. CONCLUSIONS: Eribulin shows modest activity in patients with recurrent/advanced cervical cancer with a favorable toxicity profile. Prior paclitaxel exposure is associated with decreased eribulin response. βII, βIII tubulin subtypes and BAX are predictors of response and survival. Eribulin may be an option for women with paclitaxel-naïve recurrent/advanced cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Garcia-Sayre J, Lin YG, Matsuo K, et al. Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer. Gynecol Oncol. 2023. PMID: 37079977. doi:10.1016/j.ygyno.2023.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。